Multiple Skleroz Rehabilitasyonu
Özet
Multipl Skleroz (MS), merkezi sinir sistemini etkileyen, kronik inflamatuar ve demiyelinizan nörolojik bir hastalıktır. Genç ve orta yaşlı bireylerde sıkça görülen MS, coğrafi enleme bağlı olarak ekvatordan uzaklaştıkça artan bir prevalansa sahiptir. T-hücre aracılı immün reaksiyonlar sonucu oluşan plaklar; optik sinir, serebrum, spinal kord ve beyin sapı gibi bölgeleri tutarak görme kaybı, spastisite, duyu bozuklukları, ataksi ve kognitif defisitler gibi çeşitli semptomlara yol açar. Tanıda altın standart MRG olup, BOS incelemeleri ve nörofizyolojik testler de süreci destekler. Tedavide farmakolojik yöntemlerin yanı sıra fonksiyonel bağımsızlığı korumak adına multidisipliner rehabilitasyon hayati önem taşır. Yorgunluk, spastisite, tremor, mesane-bağırsak sorunları, ağrı, ısıya duyarlılık, kas gücü kayıpları ve kognitif bozukluklar gibi semptomlar kişiye özel stratejilerle yönetilir. Bu kapsamda germe egzersizleri, aerobik ve kuvvetlendirme programları, Frenkel egzersizleri, pelvik taban eğitimleri ve yardımcı cihazlar (AFO, kanedyen, yürüteç) aktif olarak kullanılır. Erken evrede planlanan kapsamlı bir nörorehabilitasyon yaklaşımı, hastaların uzun dönem fonksiyonel kayıplarını kompanse ederek yaşam kalitelerini artırmada, sosyal ve mesleki hayata adaptasyonlarını sağlamada temel tedavi unsurudur.
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating neurological disease affecting the central nervous system, particularly prevalent among young and middle-aged adults. Its prevalence correlates with geographical latitude, showing higher incidence rates further from the equator. T-cell mediated autoimmune reactions result in plaques localized in areas such as the optic tract, cerebrum, spinal cord, and brainstem, leading to diverse symptoms including visual loss, spasticity, sensory deficits, ataxia, and cognitive impairment. While MRI remains the gold standard for diagnosis, CSF analysis and neurophysiological tests provide critical supportive data. Alongside disease-modifying pharmacological treatments, multidisciplinary neurorehabilitation is indispensable for managing long-term disability and enhancing the patient's quality of life. Diverse symptoms including fatigue, tremor, bowel-bladder dysfunctions, pain, heat sensitivity, muscle weakness, and respiratory issues are addressed through targeted non-pharmacological interventions. Therapeutic strategies leverage stretching exercises, personalized aerobic and resistance training, Frenkel exercises, pelvic floor rehabilitation, and assistive devices like AFOs or walkers. Early-initiated comprehensive rehabilitation plans effectively compensate for functional deficits, facilitating the patient's adaptation to daily, social, and professional activities.
Referanslar
Tunalı G. Epidemiyoloji. Türkiye Klinikleri J Neur 2004;2:161-5.
Ebers G, Sadovnic AD. The geographic distribution of multiple sclerosis: A review. Neuroepidemyology 1993;12:1-5.
Vercellino M, Masera S, Lorenzatti M, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol. 2009;68(5):489–502.
Trapp BD, Peterson J, Ransohoff RM,et al. Axonal transaction in the lesions of multiple sclerosis. N Engl JMed 1998;338:278-85.
Stadelmann C, Albert M, Wegner C, Bruck W. Cortical pathology in multiple sclerosis. Curr Opin Neurol. 2008;21:229–234.
Meinly E, Hohlfeld R. Immunopathogenesis of multiple sclerosis:MBP and beyond. Clin Exp Immunol 2002;128:395-7.
Selmaj KW, Raine CS. Tumor necrosis factor mediates myelinand oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-46.
Turhan N, Bayramoğlu M. Multiple skleroz. In: Oğuz H, DursunE, Dursun N, editörler Tıbbi Rehabilitasyon. Ankara: Nobel Tıp Kitabevleri; 2004. p.649-63.
Tunalı G. Multiple skleroz’da tanı kriterleri. Türkiye Klinikleri J Neur 2004;2:205-9.
Kesselring J. Neurorehabilitation in multiple sclerosis-what is the evidence-base? J Neurol 2004;251:25-9.
Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010. August;33(8):1061–7.
Vucic S, Burke D, Kiernan MC. Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol. 2010. June;121(6):809–17.
Strober LB, Christodoulou C, Benedict RH, et al. Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler. 2012. May;18(5):647–53.
Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler. 2005. October;11(5):602–9.
Branas P, Jordan R, Fry-Smith A, et al. Treatments for fatigue in multiple sclerosis: A rapid and systematic review. Health Technol Assess 2000;4:1-61.
Navipour H, Madani H, Mohebbi MR, et al. Improved fatigue in individuals with multiple sclerosis after participating in a short-term self-care program. NeuroRehabilitation 2006;21:37-41.
Kessekring J, Beer S. Symptomatic therapy and Neurorehabilitation in multiple sclerosis. Lancet Neurol 2005;4:643-52.
Krupp LB. Mechanisms Measurement and Management of Fatigue in Multiple Sclerosis; Recent Advances. Multiple Sclerosis: Clinical Challenges and Controversies (Thompson A, Polman C, Hohlfeld R, eds) London, Martin Dunitz Ltd Yayın.; 1997: 283-294
Clanet MG, Azais-Vuillemin C. What is New in the Symptomatic Management of Multiple Sclerosis?; Recent Advances. Multiple Sclerosis: Clinical Challenges and Controversies (Thompson A, Polman C, Hohlfeld R, eds) London, Martin Dunitz Ltd Yayın.; 1997: 235-242.
Bavikatte G, Gaber T. Approach to spasticity in general practice. Br. J. Med. Pract. 2009: 2(3), 29–34.
Haas J. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update Expert Rev. Neurother. 2011: 11(4 Suppl. 1), 3–8
Shakespeare D, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 2003: 4, CD001332.
Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol. Assess. 2003: 7(40),1–111.
Hugos CL, Cameron MH. MS Spasticity: Take Control (STC) for ambulatory adults: protocol for a randomized controlled trial. 2020 Oct 7;20(1):368.
Khan F, Amatya B, Stokes LT. Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis. Neurol Res Int. 2011; 2011: 740505.
Makhoul K, Ahdab R, Riachi N et al. Tremor in Multiple Sclerosis-An Overview and Future Perspectives. Brain Sci. 2020 Oct; 10(10): 722.
Thompson AJ. Progress in neurorehabilitation in multiple sclerosis. Curr Opin Neurol 2002;15:267-70.
Betts CD, D’Mellow MT, Foeler CJ; Urinary symptoms and neurological features of bladder dysfonction in multiple sclerosis, J Neurol Neurosurg Psychiatry. 1993 Mar; 56 (3) :45-50.
Chia YW, Fowler CJ, Kamm MA, et al; Prevalence of bowel dysfunciton in patients with multiple sclerosis and bladder dysfunction. Jneurol. 1995 Jan; 242(2):105-8.
Şendur ÖF, Taşçı Bozbaş G. Multiple skleroz tedavi ve rehabilitayonu.Nörolojik hastalıkların rehabilitasyonu. Göksoy T. İstanbul. İstanbul Tıp Kitabevi. 2017;1 81-96.
Fjorback MV, Rijkhoff N, Petersen T, et al. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn 2006;25:349-55.
McClurg D, Ashe RG, Marshall K, et al. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: A randomized pilot study. Neurourol Urodyn 2006;25:337-48.
Delisa JA; Physical medicine and rehabilitation: principles and practice. In: Kraft GH, Chui JY, eds. Multiple sclerosis. Philadelphia. Lippincott Willliams&Wilkins, 2005:1753-1769.
Crayton H, Heyman RA, Rossman HS.; A multimodal approach to managing the symptoms of multiple sclerosis. Neurology 2004; 63(11 suppl 5) s12-18.
Rousseaux M, Perennou D. Comfort care in severely disabled multiple sclerosis patients. J Neurol Sci 2004;222:39-48.
Nodder D, Chappell B, Bates D, et al. Multiple sclerosis: care need for 2000 and beyond. J R Soc Med 2000;93:219-24.
Stenager E,Knudsen L, Jensen K; Acuteand chronic pain syndromes in multiple sclerosis. Acta Neurol Scand. 1991 Sep; 84(3):197-200.
Donze C, Massot C. Rehabilitation in multiple sclerosis in 2021. Presse Med. 2021 Jun;50(2):104066
Chen MH, Chiravallotti ND, Deluca J. Neurological update: cognitive rehabilitation in multiple sclerosis. J Neurol 2021 Dec;268(12):4908-4914.
Yang CC; Sexual dysfunction in MS: common electtrodiagnostic findings. Int J MS Care 2002;4(2):79-80.
Zorzon M, Zivadinov R, Bosco A, et al; Axual dysfunction in multiple sclerosis: a case-control study.I. Frequency and comparison of groups. Mult Scler 1999;5: 418-27.
Foley F, Saunders A.; Sexuality, multiple sclerosis and woman. MS Manage 1997;4(1):1-10.
Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003;16:283-8.
Gilchrist AC, Creed FH.; Depression, cognitive impairment and social stres in multiple sclerosis. JPsychosom Res 1994; 38: 193-201.
Nodder D, Chappell B, Bates D, et al. Multiple sclerosis: care need for 2000 and beyond. J R Soc Med 2000;93:219-24.
Hauser SL, Cree CAB. Treatment of Multiple Sclerosis: A Review. Am J Med 2020 Dec;133(12):1380-1390.
Gosselink R, Kovacs L, Ketelaer P, et al. Respiratory muscle weakness and respiratory muscle training in severely disabled multiple sclerosis patients. Arch Phsy Med Rehabil 2000; 81: 747-51.
Taşçıoğlu F. Multiple skleroz ve rehabilitasyonu. Turkiye Klinikleri J Int Med Sci 2007, 3(10)
Motl R. Exercise and Multiple Sclerosis. Adv Exp Med Biol 2020;1228:333-343.
Kubsik-Gidlewska A , Klimkiewicz P, Klimkiewicz R et all. Rehabilitation in multiple sclerosis. Adv Clin Exp Med. 2017 Jul;26(4):709-715
Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
Gibson J, Frank A. Supporting individuals with disabling multiple sclerosis. J R Soc Med 2002;95:580-6.
